| Latest Tanox News Headlines | | Date | Time | Source | | | 08/02/2007 | 5:30PM | PRNUS | HealthShares(TM) Announces Change to the HealthShares(TM) Respiratory/Pulmonary Index
NEW YORK, Aug. 2 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the calculating agent for the HealthShares(TM) Indices, that effective at the opening of trading on Monday August 6, 2007, Matrixx Initiatives... More...>> |
| 05/09/2007 | 4:02PM | PRNUS | Tanox Reports 2007 First Quarter Results
HOUSTON, May 9 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the first quarter ended March 31, 2007.
Total revenues for the first quarter of 2007 were $18.6 million, compared to revenues of $9.8 million for the first quarter of 2006, and $18.3 million for the fourth quarter... More...>> |
| 03/15/2007 | 5:53PM | PRNUS | Tanox Reports Fourth Quarter and Full Year 2006 Results
HOUSTON, March 15 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the fourth quarter and full year 2006.
Fourth Quarter 2006 Financial Overview
Total revenues for the fourth quarter of 2006 were $18.3 million, compared to revenues of $23.0 million for the fourth quarter of... More...>> |
| 01/29/2007 | 8:36AM | PRNUS | Genentech and Tanox Receive 'Second Request' from the Federal Trade Commission
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 29 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE:DNA) and Tanox, Inc. (NASDAQ:TNOX) today announced that they have received a Request for Additional Information and Documentary Materials, commonly referred to as a "second request," from the U.S. Federal Trade Commission... More...>> |
| 01/15/2007 | 2:43PM | PRNUS | Tanox, Inc. Stockholders Approve Merger With Genentech, Inc.
HOUSTON, Jan. 15 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) (the "Company") announced today that its stockholders have voted to adopt the merger agreement providing for the merger of the Company and a wholly owned subsidiary of Genentech, Inc. (NYSE:DNA), at the Company's special meeting of stockholders held... More...>> |
| 11/09/2006 | 5:50PM | PRNUS | Genentech Announces Agreement to Acquire Tanox for $20 Per Share
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Nov. 9 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE:DNA) and Tanox, Inc. (NASDAQ:TNOX) today announced plans for Genentech to acquire Tanox, a biotechnology company specializing in the discovery and development of biotherapeutics based on monoclonal antibody technology, for... More...>> |
| 11/02/2006 | 6:30AM | PRNUS | Tanox Reports 2006 Third Quarter Results
Total Revenue Increases 84% Year Over Year
HOUSTON, Nov. 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the third quarter ended Sept. 30, 2006.
Total revenue for the third quarter of 2006 was $15.3 million, compared to revenues of $8.3 million for the third quarter of 2005... More...>> |
| 10/25/2006 | 6:00AM | PRNUS | Tanox Initiates Phase 1 Clinical Trial Evaluating TNX-650 for Treatment of Asthma
HOUSTON, Oct. 25 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) has begun dosing a Phase 1 clinical trial of TNX-650, a humanized monoclonal antibody being evaluated as a potential treatment for moderate-to-severe asthma.
The trial is a randomized, double-blind, placebo-controlled, dose- escalation study of the... More...>> |
| 10/24/2006 | 5:10PM | PRNUS | Tanox to Report Third Quarter 2006 Financial Results, Host Conference Call for Investors Nov. 2
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will report its 2006 third quarter financial results Nov. 2, 2006.
The announcement will be made prior to market open, with a conference call for the investment community to follow at 10 a.m., EST. Tanox President and Chief Executive Officer Danong... More...>> |
| 09/14/2006 | 2:03PM | PRNUS | Tanox to Present at UBS Global Life Sciences Conference
HOUSTON, Sept. 14 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will be among the featured companies presenting at the UBS Global Life Sciences Conference Sept. 25-28 in New York City.
Tanox President and Chief Executive Officer Danong Chen, Ph.D., will provide a company update at the conference Sept. 25 at 12:30... More...>> |
| 08/31/2006 | 7:00AM | PRNUS | Tanox to Present at the Bear Stearns Healthcare Conference
HOUSTON, Aug. 31 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will deliver a company presentation at the 19th Annual Bear Stearns Healthcare Conference Sept. 11-12, in New York City.
Tanox President and Chief Executive Officer Danong Chen, Ph.D., will provide a company update and take investor questions at the... More...>> |
| 08/17/2006 | 1:00PM | PRNUS | New Data Confirm Durable Response of TNX-355 Regimens Through 48 Weeks in Treatment-Experienced HIV Patients
Novel viral-entry inhibitor antibody shown to be well-tolerated
TORONTO, Aug. 17 /PRNewswire-FirstCall/ -- New data presented today by Tanox, Inc. (NASDAQ:TNOX) confirm that TNX-355, when used in combination with an optimized background regimen (OBR) of antiretroviral drugs, produced a sustained virologic response in... More...>> |
| 08/08/2006 | 5:30AM | PRNUS | Tanox Reports 2006 Second Quarter Results
Revenue Up 72% Year Over Year ---- TNX-355 Discussions With FDA Ongoing ---- Conference Call Today at 10 a.m., EDT
HOUSTON, Aug. 8 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the second quarter ended June 30, 2006.
Revenues for the second quarter of 2006 were $12.7 million... More...>> |
| 08/03/2006 | 5:45PM | PRNUS | Tanox Conducts Meeting With Food and Drug Administration Regarding Its HIV/AIDS Antibody, TNX-355
HOUSTON, Aug. 3 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) has conducted a meeting with the Food and Drug Administration (FDA) to discuss clinical-trial results and continued development of TNX-355, the company's antibody being investigated for the treatment of HIV/AIDS.
While the FDA indicated that TNX-355... More...>> |
| 07/18/2006 | 8:00AM | PRNUS | Tanox to Report Second Quarter 2006 Financial Results, Host Conference Call for Investors Aug. 8
HOUSTON, July 18 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will report its 2006 second quarter financial results Aug. 8, 2006.
The announcement will be made prior to market open, with a conference call for the financial community to follow at 10 a.m., EDT. Tanox President and Chief Executive Officer Danong... More...>> |
| 05/31/2006 | 6:21PM | PRNUS | Results of TNX-355 Combination Study Published in Antimicrobial Agents and Chemotherapy
Tanox's Novel HIV Entry Inhibitor Exhibits Synergy with Enfuvirtide to Inhibit HIV
HOUSTON, May 31 /PRNewswire-FirstCall/ -- Results from a study of Tanox's (NASDAQ:TNOX) viral-entry inhibitor antibody, TNX-355, demonstrate the investigational agent's synergy with the only currently approved viral-entry inhibitor, enfuvirtide.
(Logo:... More...>> |
| 05/23/2006 | 5:00AM | PRNUS | First Patient Dosed in Phase 1 Trial of Tanox's TNX-650
HOUSTON, May 23 /PRNewswire-FirstCall/ -- Dosing has begun in the Phase 1 clinical trial of TNX-650, a monoclonal antibody from Tanox, Inc. (NASDAQ:TNOX) for the treatment of Hodgkin's lymphoma in patients who are refractory to chemotherapy or radiation treatment.
The non-randomized, multiple-dose, dose-escalation... More...>> |
| 05/02/2006 | 5:00AM | PRNUS | Tanox Reports 2006 First Quarter Results
Quarterly Revenue Grows 66% Year Over Year
HOUSTON, May 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported financial results for the first quarter ended March 31, 2006.
Revenues for the first quarter of 2006 were $9.8 million compared to revenues of $5.9 million for the first quarter of 2005, and... More...>> |
| 05/02/2006 | 4:00AM | PRNUS | Tanox Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial
New Data Demonstrate Sustained Viral-Load Reductions, Significant Increases in CD4+ Cell Counts in Treatment-Experienced HIV Patients
HOUSTON, May 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported 48-week results of its Phase 2 clinical trial of HIV drug candidate, TNX-355. Following previously reported... More...>> |
| 04/17/2006 | 3:30PM | PRNUS | Tanox to Present at Two Investor Conferences in May
HOUSTON, April 17 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will deliver company presentations in May at Deutsche Bank's Health Care Conference in Boston and the Bank of America Health Care Conference in Las Vegas.
Tanox President and Chief Executive Officer Danong Chen will deliver a company update at the... More...>> |
|